• SPX
  • $5,751.13
  • 0.97 %
  • $55.19
  • DJI
  • $42,080.37
  • 0.3 %
  • $126.13
  • N225
  • $39,277.96
  • 0.87 %
  • $340.42
  • FTSE
  • $8,217.58
  • 0.33 %
  • $26.97
  • IXIC
  • $18,182.92
  • 1.45 %
  • $259.01
Corcept Therapeutics Incorporated (CORT) Stock Price, News & Analysis

Corcept Therapeutics Incorporated (CORT) Stock Price, News & Analysis

Currency in USD Disclaimer

$45.74

$1.08

(2.42%)

Day's range
$44.66
Day's range
$45.94
50-day range
$32.33
Day's range
$47.71
  • Country: US
  • ISIN: US2183521028
52 wk range
$20.84
Day's range
$47.71
  • CEO: Dr. Joseph K. Belanoff M.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 27.33
  • Piotroski Score 5.00
  • Grade Buy
  • Symbol (CORT)
  • Company Corcept Therapeutics Incorporated
  • Price $45.74
  • Changes Percentage (2.42%)
  • Change $1.08
  • Day Low $44.66
  • Day High $45.94
  • Year High $47.71

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 10/30/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $60.50
  • High Stock Price Target $78.00
  • Low Stock Price Target $38.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $1.05
  • Trailing P/E Ratio 31.72
  • Forward P/E Ratio 31.72
  • P/E Growth 31.72
  • Net Income $106.14 M

Income Statement

Quarterly

Annual

Latest News of CORT

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.